Listing 1 - 10 of 10 |
Sort by
|
Choose an application
Marine habitats are promising sources to identify novel organisms and compounds. A total of 70% of the planet’s surface is covered by ocean, and little is known about the biosphere within these habitats. In the last few years, numerous novel bioactive compounds or secondary metabolites from marine environments have been described. This is, and will be, a promising source of candidate compounds in pharma research and chemical biology. In recent years, a number of novel techniques have been introduced to the field and it has become easier to actually (bio-)prospect compounds such as enzyme inhibitors. Those novel compounds then need to be characterized and evaluated in comparison to well-known representatives. This Special Issue focuses on the description of novel enzyme inhibitors of marine origin, including bioprospecting, omic approaches, and structural and mechanistic aspects.
sponge Monanchora pulchra --- pentacyclic guanidine alkaloids --- GH36 α-galactosidase --- GH109 α-N-acetylgalactosaminidase --- slow-binding irreversible inhibitor --- monanchomycalin B --- monanhocidin A --- normonanhocidin A --- Alzheimer′s disease --- BACE1 --- acetylcholinesterase --- in silico docking --- phlorotannins --- Ulva intestinalis --- ACE inhibitory peptide --- optimization --- purification --- structural identification --- molecular docking --- secondary metabolites --- Mycosphaerella sp. --- asperchalasine --- α-glucosidase --- kinase inhibitors --- drug development --- marine natural products --- inhibitor --- macroalgae --- marine fish --- protease --- Ulva ohnoi --- functional annotation --- structure–function relation --- natural products --- bioactives --- enzyme inhibition --- inactivation --- marine bacteria --- marine fungi --- marine sponges
Choose an application
Marine Drugs is glad to announce its first Special Issue book on “ion channels” related research: Under the great stewardship of the Guest Editor, Dr. Jean-Marc Sabatier, four advanced research articles and three comprehensive review papers were collected in the Special Issue “Ion Channels as Marine Drug Targets”. Join us to explore the advanced research outcomes in this field: α-Conotoxin RgIA and a potent analog, RgIA4, in treatment of pain; botulinum toxin-chitosan nanoparticles in treatment of atrial fibrillation; 27-amino acid (aa)-long δ-conotoxin TxVIA that modulates mammalian CaV3.x; first venomics study of Conus tulipa venom; review on marine toxins targeting Kv1 channels; review on synthetic approaches to zetekitoxin AB; and review on marine natural products and drug resistance in latent tuberculosis. The second edition of this Special Issue is open for submissions, we look forward to your contribution.
conotoxin --- Conus tulipa --- intraspecific variation --- venomics --- transcriptomics --- proteomics --- conantokins --- net hunting strategy --- nirvana cabal --- ion channel modulators --- marine anti-TB compounds --- PZA --- MTB --- latent TB --- sponges --- nicotinic --- chemotherapy --- paclitaxel --- taxane --- neuropathic pain --- α9α10 --- saxitoxin --- zetekitoxin AB --- voltage-gated sodium channel --- guanidine alkaloid --- bioactives --- conotoxins 2 --- Kv1 --- marine toxins --- modulators --- potassium channels --- sea anemone toxins --- TxVIA --- mammalian NaV channel --- selective inhibitor --- T-type CaV3.2 --- botulinum toxin A1 --- chitosan nanoparticles --- antiarrhythmics --- pharmacological models of arrhythmia --- electrically induced arrhythmia
Choose an application
Marine Drugs is glad to announce its first Special Issue book on “ion channels” related research: Under the great stewardship of the Guest Editor, Dr. Jean-Marc Sabatier, four advanced research articles and three comprehensive review papers were collected in the Special Issue “Ion Channels as Marine Drug Targets”. Join us to explore the advanced research outcomes in this field: α-Conotoxin RgIA and a potent analog, RgIA4, in treatment of pain; botulinum toxin-chitosan nanoparticles in treatment of atrial fibrillation; 27-amino acid (aa)-long δ-conotoxin TxVIA that modulates mammalian CaV3.x; first venomics study of Conus tulipa venom; review on marine toxins targeting Kv1 channels; review on synthetic approaches to zetekitoxin AB; and review on marine natural products and drug resistance in latent tuberculosis. The second edition of this Special Issue is open for submissions, we look forward to your contribution.
Medicine --- conotoxin --- Conus tulipa --- intraspecific variation --- venomics --- transcriptomics --- proteomics --- conantokins --- net hunting strategy --- nirvana cabal --- ion channel modulators --- marine anti-TB compounds --- PZA --- MTB --- latent TB --- sponges --- nicotinic --- chemotherapy --- paclitaxel --- taxane --- neuropathic pain --- α9α10 --- saxitoxin --- zetekitoxin AB --- voltage-gated sodium channel --- guanidine alkaloid --- bioactives --- conotoxins 2 --- Kv1 --- marine toxins --- modulators --- potassium channels --- sea anemone toxins --- TxVIA --- mammalian NaV channel --- selective inhibitor --- T-type CaV3.2 --- botulinum toxin A1 --- chitosan nanoparticles --- antiarrhythmics --- pharmacological models of arrhythmia --- electrically induced arrhythmia
Choose an application
The sustainable exploitation of marine biodiversity is one structural column of the “blue economy”, and the discovery of new compounds and materials to be used in biomedicine is considered one of the most strategic activities, within an economic context. An exhaustive selection of the different typologies of approaches used by marine biotechnologists to develop research on these topics are demonstrated in the eight original articles and two reviews comprising this Special Issue. The reported scientific publications describe the discovery of new compounds for cancer therapy or for the control of bacterial virulence. Different new uses of marine chitin or chitosan-based materials are also shown for the first time, as well as novel green techniques for the extraction of compounds from marine algae or from fishery waste, which are described in the two reviews.
Technology: general issues --- Extracellular Polymeric Substances --- hydrogel --- mesenchymal stem cells --- biomaterials --- enzyme --- omega 3 --- PUFA --- Trichormus variabilis --- Cyanobacteria --- mechanochemical synthesis --- chitosan --- laser stereolithography --- long-term stability --- scaffold --- tissue reaction --- chitin --- scaffolds --- biological materials --- demosponges --- Pseudoceratina arabica --- microalgae --- biodiversity --- bioactive compounds --- green extractions --- pharmaceutical --- secondary metabolites --- biofuels --- antibiofilm --- fucoidan --- motility --- nanoparticles --- Pseudomonas aeruginosa --- virulence factors --- n-3 fatty acids --- brain --- α-Chitin --- prodigiosin --- anti-tumors --- Serratia marcescens --- bioprocessing --- echinochrome A --- estradiol --- extracellular matrix --- vocal fold --- ovariectomy --- marine polymers --- ionic liquids --- tissue engineering --- membranes --- hydrogels --- sponges --- Chondrosin --- Chondrosia reniformis --- marine toxin --- cytotoxic protein --- Porifera --- marine --- microbes --- cancer --- prevention --- therapy --- in vitro --- in vivo --- clinical studies
Choose an application
Marine habitats are promising sources to identify novel organisms and compounds. A total of 70% of the planet’s surface is covered by ocean, and little is known about the biosphere within these habitats. In the last few years, numerous novel bioactive compounds or secondary metabolites from marine environments have been described. This is, and will be, a promising source of candidate compounds in pharma research and chemical biology. In recent years, a number of novel techniques have been introduced to the field and it has become easier to actually (bio-)prospect compounds such as enzyme inhibitors. Those novel compounds then need to be characterized and evaluated in comparison to well-known representatives. This Special Issue focuses on the description of novel enzyme inhibitors of marine origin, including bioprospecting, omic approaches, and structural and mechanistic aspects.
Research & information: general --- sponge Monanchora pulchra --- pentacyclic guanidine alkaloids --- GH36 α-galactosidase --- GH109 α-N-acetylgalactosaminidase --- slow-binding irreversible inhibitor --- monanchomycalin B --- monanhocidin A --- normonanhocidin A --- Alzheimer′s disease --- BACE1 --- acetylcholinesterase --- in silico docking --- phlorotannins --- Ulva intestinalis --- ACE inhibitory peptide --- optimization --- purification --- structural identification --- molecular docking --- secondary metabolites --- Mycosphaerella sp. --- asperchalasine --- α-glucosidase --- kinase inhibitors --- drug development --- marine natural products --- inhibitor --- macroalgae --- marine fish --- protease --- Ulva ohnoi --- functional annotation --- structure–function relation --- natural products --- bioactives --- enzyme inhibition --- inactivation --- marine bacteria --- marine fungi --- marine sponges
Choose an application
The sustainable exploitation of marine biodiversity is one structural column of the “blue economy”, and the discovery of new compounds and materials to be used in biomedicine is considered one of the most strategic activities, within an economic context. An exhaustive selection of the different typologies of approaches used by marine biotechnologists to develop research on these topics are demonstrated in the eight original articles and two reviews comprising this Special Issue. The reported scientific publications describe the discovery of new compounds for cancer therapy or for the control of bacterial virulence. Different new uses of marine chitin or chitosan-based materials are also shown for the first time, as well as novel green techniques for the extraction of compounds from marine algae or from fishery waste, which are described in the two reviews.
Extracellular Polymeric Substances --- hydrogel --- mesenchymal stem cells --- biomaterials --- enzyme --- omega 3 --- PUFA --- Trichormus variabilis --- Cyanobacteria --- mechanochemical synthesis --- chitosan --- laser stereolithography --- long-term stability --- scaffold --- tissue reaction --- chitin --- scaffolds --- biological materials --- demosponges --- Pseudoceratina arabica --- microalgae --- biodiversity --- bioactive compounds --- green extractions --- pharmaceutical --- secondary metabolites --- biofuels --- antibiofilm --- fucoidan --- motility --- nanoparticles --- Pseudomonas aeruginosa --- virulence factors --- n-3 fatty acids --- brain --- α-Chitin --- prodigiosin --- anti-tumors --- Serratia marcescens --- bioprocessing --- echinochrome A --- estradiol --- extracellular matrix --- vocal fold --- ovariectomy --- marine polymers --- ionic liquids --- tissue engineering --- membranes --- hydrogels --- sponges --- Chondrosin --- Chondrosia reniformis --- marine toxin --- cytotoxic protein --- Porifera --- marine --- microbes --- cancer --- prevention --- therapy --- in vitro --- in vivo --- clinical studies
Choose an application
Marine habitats are promising sources to identify novel organisms and compounds. A total of 70% of the planet’s surface is covered by ocean, and little is known about the biosphere within these habitats. In the last few years, numerous novel bioactive compounds or secondary metabolites from marine environments have been described. This is, and will be, a promising source of candidate compounds in pharma research and chemical biology. In recent years, a number of novel techniques have been introduced to the field and it has become easier to actually (bio-)prospect compounds such as enzyme inhibitors. Those novel compounds then need to be characterized and evaluated in comparison to well-known representatives. This Special Issue focuses on the description of novel enzyme inhibitors of marine origin, including bioprospecting, omic approaches, and structural and mechanistic aspects.
Research & information: general --- sponge Monanchora pulchra --- pentacyclic guanidine alkaloids --- GH36 α-galactosidase --- GH109 α-N-acetylgalactosaminidase --- slow-binding irreversible inhibitor --- monanchomycalin B --- monanhocidin A --- normonanhocidin A --- Alzheimer′s disease --- BACE1 --- acetylcholinesterase --- in silico docking --- phlorotannins --- Ulva intestinalis --- ACE inhibitory peptide --- optimization --- purification --- structural identification --- molecular docking --- secondary metabolites --- Mycosphaerella sp. --- asperchalasine --- α-glucosidase --- kinase inhibitors --- drug development --- marine natural products --- inhibitor --- macroalgae --- marine fish --- protease --- Ulva ohnoi --- functional annotation --- structure–function relation --- natural products --- bioactives --- enzyme inhibition --- inactivation --- marine bacteria --- marine fungi --- marine sponges
Choose an application
The sustainable exploitation of marine biodiversity is one structural column of the “blue economy”, and the discovery of new compounds and materials to be used in biomedicine is considered one of the most strategic activities, within an economic context. An exhaustive selection of the different typologies of approaches used by marine biotechnologists to develop research on these topics are demonstrated in the eight original articles and two reviews comprising this Special Issue. The reported scientific publications describe the discovery of new compounds for cancer therapy or for the control of bacterial virulence. Different new uses of marine chitin or chitosan-based materials are also shown for the first time, as well as novel green techniques for the extraction of compounds from marine algae or from fishery waste, which are described in the two reviews.
Technology: general issues --- Extracellular Polymeric Substances --- hydrogel --- mesenchymal stem cells --- biomaterials --- enzyme --- omega 3 --- PUFA --- Trichormus variabilis --- Cyanobacteria --- mechanochemical synthesis --- chitosan --- laser stereolithography --- long-term stability --- scaffold --- tissue reaction --- chitin --- scaffolds --- biological materials --- demosponges --- Pseudoceratina arabica --- microalgae --- biodiversity --- bioactive compounds --- green extractions --- pharmaceutical --- secondary metabolites --- biofuels --- antibiofilm --- fucoidan --- motility --- nanoparticles --- Pseudomonas aeruginosa --- virulence factors --- n-3 fatty acids --- brain --- α-Chitin --- prodigiosin --- anti-tumors --- Serratia marcescens --- bioprocessing --- echinochrome A --- estradiol --- extracellular matrix --- vocal fold --- ovariectomy --- marine polymers --- ionic liquids --- tissue engineering --- membranes --- hydrogels --- sponges --- Chondrosin --- Chondrosia reniformis --- marine toxin --- cytotoxic protein --- Porifera --- marine --- microbes --- cancer --- prevention --- therapy --- in vitro --- in vivo --- clinical studies
Choose an application
Cyanobacteria are a group of ubiquitous photosynthetic prokaryotes. Their occurrence has been increasing worldwide, due to anthropogenic activities and climate change. Several cyanobacterial species are able to synthesize a high number of bioactive molecules, among them, cyanotoxins (microcystins, cylindrospermopsin, nodularin, etc.), which are considered a health concern. For risk assessment of cyanotoxins, more scientific knowledge is required to perform adequate hazard characterization, exposure evaluation and, finally, risk characterization of these toxins. This Special Issue “Cyanobacteria and Cyanotoxins: New Advances and Future Challenges” presents new research or review articles related to different aspects of cyanobacteria and cyanotoxins, and contributes to providing new toxicological data and methods for a more realistic risk assessment.
method validation --- sirtuin 1 (SIRT1) --- arctic --- Cylindrospermopsin --- Microcystin-LR --- 16S rRNA gene --- astaxanthin --- secondary metabolites --- shotgun metagenomic sequencing --- time-resolved fluoroimmunoassay --- Histopathological evaluation --- cyanobacterial thresholds --- akinetes --- nutrient enrichment --- benthic mats --- cylindrospermopsin --- drinking water treatment plant --- blue-green algae supplements --- lettuce --- genotoxicity --- exposure --- bacterial community --- PCR --- microcystin-LR --- marine natural compounds --- ELISA --- [d-Leu1]Microcystin-LR --- Paracentrotus lividus --- tadpoles --- apoptosis --- 16S rRNA gene sequencing --- PSP toxins --- marine cyanobacteria --- hemolytic essay --- energy budget --- bioassays --- anatoxin-a --- Lithobates catesbeianus --- mixture --- reproductive toxicity --- cyanobacteria --- taste-and-odor compounds --- Procambarus clarkii --- drinking water --- saxitoxin --- resveratrol --- harmful algal blooms --- cytotoxicity --- phylogenetic analyses --- Yangtze estuary --- microcystin --- mutagenicity --- detection --- Artemia salina --- water source --- cyanotoxins --- microcystins --- in vitro --- marine sponges --- microcystin-LR (MC-LR) --- UPLC-MS/MS --- reservoir --- microbial metabolisms --- Aphanizomenon flos-aquae --- monoclonal antibody --- oxidative stress --- Nostocales
Choose an application
In 2019, we sent out a call for submissions to a Special Issue of Marine Drugs entitled “Marine Chitin 2019”, and we are pleased that this issue has now been published. Over 16 high-impact papers were included in this issue, which we now plan to publish as a book. In addition, we now seek to publish a further Special Issue of Marine Drugs, “Marine Chitin 2020–2021”. As before, we plan to produce an authoritative and exciting issue that will encompass breakthroughs in scientific and industrial chitin and chitosan research. Significant advances in chitin and chitosan research have been made since the 1970s, and current overviews in recent publications involving chitin and chitosan research advances are in need of an update.
chitosan hydrogel --- chitosan --- biotechnology --- RAW264.7 macrophage --- ?-glucosidase inhibitor --- bromotyrosines --- layer-by-layer film --- amphiphilic polymer --- conjugation --- marine resources --- antioxidant activity --- chitooligosaccharides --- methylene blue --- nanoparticles --- bulk density --- Eudragit® S100 --- lytic polysaccharide monooxygenase --- chitosan oleate salt --- curcumin --- RAW 264.7 cells --- antioxidant --- crude oil --- ball milling --- anti-inflammatory action --- enzymatic modification --- dissolution --- vaginal infections --- Hausner ratio --- crushing strength --- Staphylococcus epidermidis --- mucoadhesive film --- Caco-2 cell culture --- chitosan lactate --- 2D correlation spectroscopy --- chitosan citrate --- direct compression --- chitosan oligomers --- chitin deacetylase --- Pseudomonas aeruginosa --- collagen --- blood --- express method --- sodium carbonate --- HIV sexual transmission --- streptomycin --- antibacterial activity --- pork sausage --- nanocomposites --- chitosanase --- Clostridium perfringens --- chitinase --- mucoadhesion --- chitosan oligosaccharides --- chitosan tartrate --- Staphylococcus aureus --- immunostimulatory activity --- derivatization --- pH responsive release --- soluble chitosan complex --- chitin --- polymer film --- compression work --- wound treatment --- biofilms --- roller compaction --- mitogen-activated protein kinases (MAPK) --- Paenibacillus --- chitooligosaccharide --- mechanical property --- protease --- Polybius henslowii --- scaffolds --- electrospinning --- chitosan-coated liposomes --- phosphoinositide 3-kinases (PI3K)/Akt --- cytotoxicity --- polymorph --- vaginal preexposure prophylaxis --- Aplysina archeri --- antifungal activity --- PLGA --- Kawakita analysis --- marine sponges --- Tenofovir controlled release --- nile red
Listing 1 - 10 of 10 |
Sort by
|